GNLX

#3925
Genelux Corporation Common Stock
2.64 USD
+4.35%
Сектор: Здравоохранение
Базовая: USD
Валюта прибыли: USD
Дневной диапазон
2.64
2.64
Годовой диапазон
2.25
8.54
Дневное изменение
+4.35%
Месячное изменение
0.00%
6-месячное изменение
-50.00%
Годовое изменение
+5.18%
Предыдущее закрытие
2.53
Открыть
2.64
Bid
Ask
Минимум
2.64
High
2.64
Объем
9
Открыть полный график

Financials

Обзор Отчетность Статистика
Квартал Год
Отчет о доходах Баланс Денежный поток
Значение 202320242025 TTM

Genelux Corporation

Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity. The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME.

Новости